Kristina Maas-Bauer
Principal Investigator
Department of Hematology, Oncology and Stem-Cell Transplantation
Medical Center University of Freiburg
Hugstetter Straße 55
79106 Freiburg i. Brsg.
- +49 761/270-34020
- kristina.maas-bauer@uniklinik-freiburg.de
- Homepage
Current position
Junior Group Leader Department of Hematology and Oncology, Medical Center University of Freiburg
Academic training
| 2007–2012 | Medical Study at University of Freiburg, Freiburg, Germany |
| 2005–2007 | Medical Study at Ulm University, Ulm, Germany |
Advanced academic qualifications
| 2012 | Dissertation in Medicine (Prof. Dr. Zeiser) University of Freiburg, Freiburg, Germany |
Postgraduate positions
| 2023 | Board certification in Internal Medicine, Hematology and Oncology |
| 2022 | Principal Investigator, Dept. of Hematology and Oncology, Freiburg |
| 2018–2023 | Clinical Fellow, Dept. of Hematology and Oncology, Freiburg |
| 2015–2018 | Postdoctorate, Stanford University School of Medicine (Lab of Dr. Negrin), BMT Dept., USA |
| 2012–2015 | Residency in Internal Medicine, Dept. of Hematology and Oncology, Freiburg |
Miscellaneous (Honors, Awards)
| Since 2024 | IMMediate Program for advanced Clinician Scientists,(funded by Bundesministerium für Bildung und Forschung, funding period 05/24-03/30) |
| 2022 | Jon van Rood Award, EBMT Annual Meeting |
| 2021 | Berta-Ottenstein-Program for Clinician Scientists (Faculty of Medicine Freiburg University, funding period 01/21-12/23) |
| 2020 | Fill-in-the-Gap-Scholarship (Faculty of Medicine Freiburg University, funding period 11-12/20) |
| 2019 | Best Abstract Award, ASTCT Annual Meeting, USA |
| 2018 | Abstract Achievement Award, ASH Annual Meeting, San Diego, USA |
| 2018 | EIRA Program (Mentoring Program for Women in Science; 10/18-05/20) |
| 2015 | Mildred-Scheel-Postdoctoral Scholarship (German Cancer Aid, funding period 09/2015–08/2018) |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Gawron J, Czech M, Rückert T, Holzmüller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Köhler N, Ayuk FA, Schell C, Quante M, Zeiser R. Gastrin for the treatment of acute graft-versus-host disease of the stomach. Blood. 2026 Apr 9;147(15):1763-1778. doi: 10.1182/blood.2025031080.
Highlighted by: Chakraverty R. GVHD fails the acid test. Blood. 2026 Apr 9;147(15):1660-1662.
Fetsch V, Schwöbel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Köhler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Färber J, Braun LM, Zähringer A, Lübbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kühn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712.
Highlighted by: Chakraverty R. Menin inhibitors: a 2-in-1 defense versus AML immune evasion. Blood (2026) 147 (5): 482–483.
Contact
